Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Passes On Oncology Price Cap Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Celgene will not follow the lead of Amgen and Genentech by instituting a price cap on its oncology drugs.

You may also be interested in...



Celgene Raises Revlimid Price Across The Board

The firm says the increases reflect inflation, cost of patient assistance and RevAssist risk management programs.

Celgene Raises Revlimid Price Across The Board

The firm says the increases reflect inflation, cost of patient assistance and RevAssist risk management programs.

Genentech Adds Patient Assistance Program Along With Avastin Lung Cancer Indication

Program similar to Amgen’s for Vectibix.

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel